Yazılar

Schrodinger to Integrate Eli Lilly’s AI Drug Discovery Platform TuneLab

/in /tarafından

Biotech software company Schrodinger said on Friday it is collaborating with pharmaceutical giant Eli Lilly to offer Lilly’s artificial intelligence–based drug discovery platform, TuneLab, through its software.

Under the collaboration, Lilly’s TuneLab platform will be integrated into Schrodinger’s cloud-based drug design software LiveDesign, giving biotechnology companies direct access to AI tools designed to accelerate drug discovery and development. Schrodinger said the integration will help researchers move more quickly from early-stage molecule design to viable drug candidates.

LiveDesign is used by chemists to design compounds and predict key properties such as absorption and distribution, helping developers understand how experimental drugs are likely to behave in the body. The addition of TuneLab is expected to further enhance these capabilities by applying AI and machine learning models trained on years of pharmaceutical research data.

Drugmakers and biotech firms have been increasingly adopting AI tools to speed up discovery and safety testing, aiming to reduce costs and development timelines. The trend aligns with efforts by regulators such as the U.S. Food and Drug Administration to encourage alternatives to animal testing in the coming years.

Schrodinger Chief Strategy Officer Karen Akinsanya said existing LiveDesign customers will gain access to TuneLab in the first quarter of this year, while new users will be able to use the AI platform starting in the second quarter.

Eli Lilly launched TuneLab last year to allow external biotech companies to tap into its AI and machine learning models trained on proprietary research data. Lilly has already announced multiple partnerships using the platform to support drug development efforts.

“More biotechs using the models means more diverse training data,” said Aliza Apple, global head of Lilly TuneLab. “Ultimately, this is about moving molecules through discovery faster for the patients who are waiting.”

Eli Lilly Unveils AI-Powered TuneLab to Speed Drug Discovery

/in /tarafından

Eli Lilly (LLY.N) announced on Tuesday the launch of TuneLab, an artificial intelligence and machine learning platform designed to give biotech companies access to advanced drug discovery models trained on decades of Lilly’s research data.

The platform represents more than $1 billion in proprietary data investments and aims to level the playing field by letting smaller biotech firms access the same AI-driven tools Lilly scientists use internally.

“Lilly TuneLab was created to be an equalizer so that smaller companies can access some of the same AI capabilities used every day by Lilly scientists,” said Daniel Skovronsky, Lilly’s chief scientific officer.

Two biotech firms — Circle Pharma and insitro — are already early partners. Circle will apply TuneLab’s tools to cancer drug development, while insitro will contribute new AI models for small molecule discovery, enhancing TuneLab’s capabilities.

The move reflects a broader industry shift toward AI in research and development. Analysts at Jefferies forecast that AI-related R&D spend could reach $30–40 billion by 2040, as drugmakers adopt AI for discovery, testing, and reducing reliance on animal studies, in line with FDA goals.

TuneLab operates on datasets covering hundreds of thousands of unique molecules. In exchange for access, biotech partners provide their own training data, further strengthening the platform’s predictive power and long-term value.